2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Shafagati N, Koh M, Boussi L, Park H, Stuver R, Bain P, Foss FM, Shen C, Jain S. Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis. Blood Advances 2022, 6: 4740-4762. PMID: 35816645, PMCID: PMC9631658, DOI: 10.1182/bloodadvances.2022007425.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaOverall response rateR Peripheral T Cell LymphomaCombination chemotherapyT-cell lymphomaSingle agentComparative efficacyRefractory T-cell lymphomaPhase ISingle-agent strategyPhase II trialPlatinum-based regimensPhase III trialsPhase I trialOptimal treatment strategyNovel single agentsRandom-effects modelSignificant subgroup differencesII trialIII trialsI trialHistological subtypesTreatment paradigmClinical trialsDrug classes
2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker Research 2014, 2: 16. PMID: 25279222, PMCID: PMC4181623, DOI: 10.1186/2050-7771-2-16.Peer-Reviewed Original ResearchMajority of discontinuationsCommon adverse eventsRefractory PTCLAdverse eventsT-cell lymphomaHematologic toxicityAE profileRomidepsin treatmentGreater incidencePoor bone marrow reserveCutaneous T-cell lymphomaRefractory T-cell lymphomaBone marrow reserveDose of romidepsinFrequent hematologic toxicityLeast stable diseaseSimilar AE profilesTreatment cycles 1Severe hematologic toxicityDurable clinical responsesRefractory aggressive lymphomaOverall clinical benefitCycle 1Overall AE profileNovel drug therapies